Three Days of Industry Innovation and Networking, From Global Market Insights to Advanced Feed Solutions and Smart Farming

KUALA LUMPUR, Malaysia, Aug. 27, 2025 /PRNewswire/ — Livestock Malaysia 2025, the Malaysian International Feed, Livestock & Meat Industry Trade Show, opened today at the Kuala Lumpur Convention Centre (KLCC). Organised by Informa Markets Malaysia, the three-day event brings together over 200 leading brands and companies representing 30+ countries. The event is expected to attract more than 6,000 industry professionals, innovators, and stakeholders eager to explore the latest technologies and market trends shaping Southeast Asia’s livestock sector.

As the region’s premier platform for the feed, livestock, and meat value chain, the exhibition showcases cutting-edge technologies, sustainable practices, and market-ready solutions to help producers thrive in an increasingly competitive and resource-constrained environment.

The Opening Ceremony featured YB Dato’ Sri Arthur Kurup, Deputy Minister of Agriculture and Food Security, as Guest of Honour, who outlined Malaysia’s ambitious vision for the sector.

“Half a century ago, Malaysia transformed from an agricultural economy to an industrial powerhouse. Today, we stand at the threshold of a new transformation: becoming a high-tech livestock industry capable of feeding not just our nation, but the wider region,” said YB Dato’ Sri Arthur Kurup.

He highlighted key priorities, including local feed production, palm-based alternative protein development, adoption of precision farming, automation, strengthened biosecurity, and enhanced veterinary capabilities.

With Southeast Asian livestock demand projected to grow 25% by 2030, the industry faces mounting pressures from rising feed costs for imported corn and soybeans, heavy reliance on imported feeder cattle, and transboundary animal diseases. Livestock Malaysia 2025 directly addresses these challenges by serving as a comprehensive solutions hub, connecting industry stakeholders with technologies, partnerships, and strategies designed to build resilience and drive sustainable growth.

“Livestock Malaysia 2025 represents a pivotal moment for our industry,” said Tan Sri Abdul Rahman Mamat, Chairman of Informa Markets Malaysia. “We’re connecting Malaysian farmers with global technologies that can immediately impact their operations, from reducing feed costs to improving animal health outcomes.”

Dr. Aida Muhid, Senior Director of the Department of Veterinary Services Malaysia, reinforced the collaborative approach essential for industry transformation: “We see every farmer as a partner, every integrator as a collaborator, and every industry player as an ally. We are here to remove barriers, not create them – while upholding the highest standards.”

The event features an extensive programme designed to deliver maximum value to attendees. The Technical Seminars, International Livestock Forum, and Association Seminars provide participants with valuable insights into the latest trends, market dynamics, and best practices in livestock management. These educational components complement the exhibition floor, creating a comprehensive learning environment where attendees can gain practical knowledge to make informed business decisions.

Adding to this, the Malaysia Livestock Industry Awards will shine a spotlight on excellence, recognising individuals and organisations whose contributions are driving the sector forward.

Meanwhile, the International Pavilions are a key feature, showcasing a range of innovations from smart feeding systems to advanced biosecurity measures. This gives local livestock farmers the chance to explore global best practices and discover new solutions to improve their operations.

The event aligns with Malaysia’s National Agro-Food Policy 2021-2030, which targets 60% self-sufficiency in key protein sources. Dr. Aida Muhid articulated this vision: “Let us see the future we are building together – where Malaysian livestock products are recognised for quality across Southeast Asia and beyond, where our farms model sustainability and efficiency, and where every Malaysian has access to safe, affordable, locally-produced protein.”

Beyond showcasing innovation, Livestock Malaysia 2025 serves as a business catalyst, with dedicated networking sessions designed to forge partnerships between local producers and international technology providers, creating sustainable growth opportunities in Southeast Asia’s expanding livestock sector.

Livestock Malaysia 2025 runs from 27-29 August 2025 at the Kuala Lumpur Convention Centre. Trade visitors are encouraged to register and participate in this transformative industry event to discover new opportunities, gain valuable insights, and connect with the professionals shaping the future of the livestock sector.

For registration and more information, visit https://www.livestockmalaysia.com/ or contact the organising team at Informa Markets Malaysia.

Notes to Editors:

About Livestock Malaysia

Since 2001, Livestock Malaysia has become the nation’s premier exhibition and conference for the feed, livestock, and meat industries. This leading event, formerly known as Livestock Asia, brings together key players – from farmers and producers to suppliers and government agencies. Organised by Informa Markets, the event features the latest technologies, targeted technical seminars, and high-value networking to tackle industry challenges and promote sustainable growth. With its focus on innovation, education, and collaboration, Livestock Malaysia continues to strengthen and advance the regional livestock community toward a resilient and prosperous future.

About Informa Markets

Informa Markets creates platforms for industries and specialist markets to trade, innovate, and grow. As a global leader in exhibitions, conferences, and B2B events, Informa Markets brings together buyers and sellers across a wide range of industries, helping businesses connect, discover new opportunities, and drive meaningful partnerships. With a portfolio spanning over 450 international events and brands across markets including healthcare, infrastructure, food, hospitality, automotive, and more, Informa Markets delivers trusted platforms that support business growth and industry development worldwide.

NEW YORK, Aug. 27, 2025 /PRNewswire/ — Future FinTech Group Inc. (NASDAQ: FTFT), (hereinafter referred to as “Future FinTech”, “FTFT” or the “Company”), a comprehensive financial and digital technology service provider, announced today that its special meeting of shareholders will take place on September 2, 2025 at 10:00 a.m. Hong Kong time (or 10:00 p.m. Eastern Standard Time), at the Company’s corporate headquarters, located at 02B-03A, 23/F, Sino Plaza, 255-257 Gloucester Road, Causeway Bay, Hong Kong, Special Administrative Region, People’s Republic of China.

We encourage all shareholders as of the record date at the close of business on July 2, 2025 to submit their vote by accessing their Proxy Card which can be found on page ANNEX A of the Company’s Proxy Statement that has been mailed to shareholders of record. The Shareholders’ Proxy Card on page ANNEX A can also be accessed via the Company’s Proxy Statement filed with the SEC at sec.gov/Archives/edgar/data/1066923/000121390025073438/ea0250682-02.htm#T99110 which contains instructions on how to vote online, by email, by fax and by mail.

About Future Fintech Group Inc.

Future FinTech Group Inc. (NASDAQ: FTFT) is a comprehensive financial and digital technology service provider. The Company, through its subsidiaries, conducts brokerage and investment banking services in Hong Kong, and engages in supply chain trading and finance businesses in China and efficient digital financial services. For more information, please visit www.ftft.com.

Safe Harbor Statement

Certain statements made in this press release are “forward-looking statements” within the meaning and protections of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Forward-looking statements include statements regarding our beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions, and future performance, and involve known and unknown risks, uncertainties, and other factors that may be beyond our control, which may cause the actual results, performance, capital, ownership, or achievements of the Company to be materially different from those implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be forward-looking statements. You can identify these forward-looking statements by our use of words such as “may,” “will,” “anticipate,” “assume,” “should,” “indicate,” “would,” “believe,” “contemplate,” “expect,” “estimate,” “continue,” “plan,” “point to,” “project,” “could,” “intend,” “target” and other similar words and expressions relating to the future.

All written or oral forward-looking statements attributable to us are expressly qualified in their entirety by this cautionary notice, including, without limitation, the risks and uncertainties described in our annual report on Form 10-K for the year ended December 31, 2024 and our other reports and filings with the SEC. Such reports are available upon request from the Company, or from the Securities and Exchange Commission, including through the SEC’s Internet website at http://www.sec.gov. We have no obligation and do not undertake to update, revise, or correct any of the forward-looking statements after the date hereof, or after the respective dates on which any such statements are otherwise made.

• Strategic joint venture aims to bring MUSINSA STANDARD and Musinsa Store to Chinese consumers
• Transaction set for completion by September 2025, subject to regulatory approval

SEOUL, South Korea, Aug. 27, 2025 /PRNewswire/ — MUSINSA has officially entered the Chinese market through a strategic partnership with ANTA Sports, a global leading company and the largest sportswear group in China.

Under the agreement, MUSINSA and ANTA Sports will jointly invest in a joint venture company, MUSINSA China, to drive business development in the Chinese market. The transaction is expected to be completed by the end of September 2025, subject to regulatory approval.

MUSINSA will hold 60% equity interests of the joint venture, becoming the majority shareholder, while ANTA Sports will hold the remaining 40%. MUSINSA China will oversee both the online and offline expansion of MUSINSA STANDARD and Musinsa Store in the Chinese market, while ANTA Sports will exercise strategic and financial oversight through representatives on the joint venture’s board of directors.

This partnership reflects the shared strategic interest of both companies to strengthen their presence in the rapidly evolving Chinese market. As Korea’s leading fashion platform with over 10,000 brands, MUSINSA plans to actively support the entry of promising Korean designer brands into China.

ANTA Sports is a leading sportswear group in China, renowned for its successful execution of a ‘multi-brand’ strategy. With deep expertise in managing a diverse portfolio of brands across performance sportswear, athleisure, and lifestyle sportswear segments—spanning both premium and mass markets—ANTA Sports is well positioned to capture evolving consumer trends. This joint venture creates an opportunity to further leverage the convergence of sportswear and fashion, while addressing the segmented and dynamic needs of younger consumers through strategic investment.

Wu Yonghua, Co-CEO of ANTA Sports, commented: “This strategic investment partnership with MUSINSA marks another step forward in advancing our ‘Single-Focus, Multi-Brand, and Globalization’ strategy. By integrating sportswear with fashion-forward design, we aim to better meet the preferences of China’s younger generation.” He emphasized that, “Leveraging our full value chain capabilities and proven ‘Brand + Retail’ operating model in the sportswear industry, ANTA Sports will empower MUSINSA China to introduce MUSINSA STANDARD and Musinsa Store to the Chinese market—bringing differentiated, style-conscious offerings to a new generation of sport and lifestyle consumers.”

Joonmo Park, CEO of MUSINSA, noted, “The partnership will combine MUSINSA’s extensive experience in fashion with ANTA’s robust brand and retail management capabilities to tap into various retail channels and deliver differentiated brand experiences to Chinese consumers.” He added, “We are looking forward to capturing the attention of young consumers in the dynamic Chinese market.” 

• Held 2025 CEO Investor Day on 27^th presenting its future growth strategy based on its “New Vision” of leading the mobility paradigm.
• Emphasized its strategy to lead the market with leading technologies such as windshield displays, SDV solutions, and BSA, which completely blocks heat transfer
• Planning to strengthen its independent capabilities in automotive semiconductors(systems/power) and pursue entry into the actuator market, a core component in the robotics field.
• Operating a profit and loss management system at all stages from product development to mass production expanding orders in high-growth emerging markets such as China and India.

SEOUL, South Korea, Aug. 27, 2025 /PRNewswire/ — Hyundai Mobis held its 2025 CEO Investor Day on August 27, bringing together investors, analysts, and credit rating agencies to present its long-term growth strategy under the new vision of leading the future mobility paradigm. President and CEO Lee Gyu-suk outlined strategic directions focused on three pillars: strengthening technology competitiveness, improving profitability, and expanding its global customer base.

• Hyundai Mobis is currently building a lineup of leading-edge technologies, including windshield displays and SDV solutions.

The company is currently concentrating on advanced technologies in key future mobility areas—electrification, electronics, semiconductors, and robotics. A standout innovation is its next-generation windshield display, which uses holographic optical film to transform the windshield into a transparent screen. First unveiled at CES 2025, this technology is being co-developed with German optics firm ZEISS and is expected to launch around 2029.

In the software-defined vehicle(SDV) sector, Hyundai Mobis is developing a standardized platform based on its advanced E/E architecture, enabling software-based control across various vehicle types. Full-scale commercialization is targeted after 2028, following platform development and vehicle demonstrations.

In electrification, the company is enhancing battery safety with systems that block heat transfer between cells using fire-resistant materials, and an automatic fire suppression system that activates upon ignition. These innovations aim to improve customer experience and reinforce Hyundai Mobis’ leadership in future mobility technologies.

• Hyundai Mobis plans to actively promote its automotive semiconductor and robotics business, “We will seize future growth opportunities.”

Hyundai Mobis also announced plans to strengthen its competitiveness in next-generation automotive semiconductors and robotics. In semiconductors, it is pursuing a two-track strategy: system semiconductors and power semiconductors. The company is developing Communication SoCs and Battery Monitoring ICs, while accelerating in-house mass production of power semiconductors—critical components for EV drive systems.

To date, Hyundai Mobis has developed 16 types of semiconductors and plans to produce 20 million units this year. Its R&D process has earned the highest ISO 26262 safety rating, and it is currently developing 11 next-generation chips. The company is also working to build a domestic semiconductor ecosystem through partnerships with automakers, fabless firms, and foundries, and will host a dedicated forum next month.

In robotics, Hyundai Mobis announced its entry into the actuator market, leveraging its expertise in vehicle steering systems. Actuators, which control robot movement, share core components with electronic steering systems and account for over 60% of humanoid robot production costs. Starting with actuators, the company plans to expand into sensors and controllers.

• Hyundai Mobis plans to actively promote its automotive semiconductor and robotics business, “We will seize future growth opportunities.”

To support sustainable growth, Hyundai Mobis is restructuring its business portfolio with a focus on profitability. It aims to achieve over 8% annual sales growth and a 5–6% operating profit margin by 2027 through product specialization and resource reallocation toward future core technologies. The company is currently evaluating the competitiveness of around 60 products and enhancing its profit management system across all stages—from development to mass production.

Hyundai Mobis also plans to strengthen its global presence by increasing the share of global customers in core parts sales to 40% by 2033. It will deepen partnerships in North America and Europe and expand orders in high-growth markets like China and India through localized product strategies and supply chain reinforcement.

Lastly, the company reaffirmed its commitment to maximizing shareholder value. This year, Hyundai Mobis repurchased and canceled treasury shares worth 620 billion won—nearly four times last year’s amount—demonstrating its dedication to transparent and predictable shareholder return policies, including dividends and buybacks. Hyundai Mobis will continue to actively implement its transparent and predictable shareholder return policy based on trust with its shareholders.

About Hyundai Mobis

Hyundai Mobis is the global no. 6 automotive supplier, headquartered in Korea. It has outstanding expertise in sensors, sensor fusion in ECUs and software development for safety control. The company’s products also include various components for electrification, brakes, chassis and suspension, steering, airbags, lighting, and automotive electronics. It operates its R&D headquarters in Korea, with four technology centers in the United States, Germany, China, and India. For more information, please visit the website at http://www.mobis.com.

Media Contact 
Choon Kee Hwang: ckhwang@mobis.com
Jihyun Han: jihyun.han@mobis.com

Phase 2b/3 Alzheimer’s trial enrolment passes 50% – twenty US trial sites continuing to recruit participants

SYDNEY, Aug. 27, 2025 /PRNewswire/ — Actinogen Medical Limited (ASX: ACW) announces that a recent trial designed to confirm therapeutic blood levels of the intended commercial tablet formulation of Xanamem®, given both with and without food, demonstrated the expected blood levels or “exposure”, comparable with prior studies of a capsule formulation. This indicates that 10 mg once daily remains the target therapeutic dose for the clinical program.

The trial was conducted at the CMAX clinical research center in Adelaide, Australia where 16 individuals were studied on two occasions, one week apart. Each received a 10 mg tablet of Xanamem once while fasting and once after a high fat meal. Blood levels of Xanamem were then measured frequently over the ensuing 48 hours.

Key results include the median time to maximum blood concentration of 4 to 6 hours (4 hours fasted, 6 hours after a high fat meal), and very similar Xanamem exposures (area under the concentration-time curve) and elimination half-life of 15 hours in both fed and fasted situations.

Professor Paul Rolan, Actinogen’s Clinical Pharmacologist commented:

“This trial confirmed that the intended commercial formulation of Xanamem produces consistent and therapeutic levels in the blood that are similar when given with or without food, giving full flexibility for dosing. These data support the use of the 10 mg daily dose irrespective of food intake in the ongoing XanaMIA phase 2b/3 trial in people with mild to moderate Alzheimer’s disease. Xanamem is a remarkable oral therapeutic with low drug interaction potential, and a 15-hour half-life suitable for once daily dosing in an elderly population.”

XanaMIA phase 2b/3 Alzheimer’s disease trial progress

Enrolment in the pivotal XanaMIA phase 2b/3 Alzheimer’s disease (AD) clinical trial has passed 55% as at the end of July 2025.

The trial is enrolling 220 participants with elevated levels of the blood biomarker pTau181, designed to identify participants with biomarker-positive AD whose disease is likely to progress during the 36-week treatment period of the trial, and therefore augment the ability to detect a Xanamem (emestedastat) treatment benefit. The primary endpoint of the trial is the Clinical Dementia Rating – Sum of Boxes scale, universally included in contemporary AD trials. Other measures include the effects of Xanamem on clinical endpoints of cognition and functional ability.

A planned safety and efficacy futility interim analysis of all available data by an independent Data Monitoring Committee will occur in January 2026.

Final results for the full enrolment of 220 participants are expected in Q4 2026.

How to enrol in the XanaMIA phase 2b/3 Alzheimer’s disease trial in the US

Actinogen is encouraging individuals and their loved ones affected by Alzheimer’s disease to take part in a groundbreaking clinical trial that could transform the way we treat this devastating condition.

The trial is enrolling people diagnosed with mild to moderate Alzheimer’s disease, offering them a chance to participate in cutting-edge research aimed at stabilizing the cognitive and functional decline of Alzheimer’s.

Xanamem inhibits the production of the “stress hormone”, cortisol, in key areas of the brain that are linked to memory and critical thinking. Watch a two-minute explainer video on how Xanamem works here.

The trial involves taking a single pill once a day of Xanamem or matching placebo (“sugar pill”) and a series of clinic visits for the assessment of Alzheimer’s progress. It does not involve frequent brain scans or complicated procedures such as lumbar puncture.

All participants at the end of the XanaMIA trial are eligible for Actinogen’s open-label extension trial of active Xanamem for up to 24 months. This extension trial will open to completed XanaMIA participants in early 2026.

Who can join?

• Individuals aged 50 or older with a diagnosis of mild to moderate Alzheimer’s disease
• Participants with a study partner willing to attend clinic visits
• Additional eligibility criteria apply

You can find out more information in these ways:

• Check eligibility: https://app.clinials.io/en-US/alzheimers
• Email Actinogen’s clinical trials team: clinicaltrials@actinogen.com.au
• Trial website link: https://actinogen.com.au/xanamia-phase-2b-trial/

About Actinogen Medical

Actinogen Medical (ACW) is an ASX-listed, biotechnology company in the late clinical stages of development for Xanamem® (emestedastat), its novel oral therapy for Alzheimer’s disease and depression. The Company is based in Sydney, Australia with operations and clinical trials in Australia and the US. Xanamem, has been studied in eight clinical trials with more than 400 people treated to date and has a promising safety and efficacy profile. ACW’s ongoing clinical trial, XanaMIA, is a phase 2b/3 trial of 220 participants with mild to moderate Alzheimer’s disease (AD) and is currently enrolling in Australia and the US. To find out more about the trial click here.

About Xanamem (emestedastat)

Xanamem’s novel mechanism of action is to control the level of cortisol in the important areas of the brain through the inhibition of the cortisol synthesis enzyme, 11β-HSD1, without blocking normal production of cortisol by the adrenal glands. Xanamem is a first-in-class, once-a-day pill designed to deliver high levels of brain cortisol control in regions where 11β-HSD1 is highly expressed such as the hippocampus. Chronically elevated cortisol is associated with progression in Alzheimer’s Disease and excess cortisol is known to be toxic to brain cells. Elevated cortisol is also associated with depressive symptoms. Xanamem has demonstrated excellent brain target engagement and in human trials has shown potential to slow progression of Alzheimer’s disease and improve depressive symptoms in patients with moderately severe depression. To view Xanamem’s two-minute Mechanism of Action video, click here.

Xanamem is an investigational product and is not approved for use outside of a clinical trial by the FDA or by any global regulatory authority. Xanamem® is a trademark of Actinogen Medical.

List of XanaMIA phase 2b/3 trial clinical sites in the US

To check eligibility: https://app.clinials.io/en-US/alzheimers

Disclaimer

This announcement and attachments may contain certain “forward-looking statements” that are not historical facts; are based on subjective estimates, assumptions and qualifications; and relate to circumstances and events that have not taken place and may not take place. Such forward looking statements should be considered “at-risk statements” – not to be relied upon as they are subject to known and unknown risks, uncertainties and other factors (such as significant business, economic and competitive uncertainties / contingencies and regulatory and clinical development risks, future outcomes and uncertainties) that may lead to actual results being materially different from any forward looking statement or the performance expressed or implied by such forward looking statements. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Actinogen Medical does not undertake any obligation to revise such statements to reflect events or any change in circumstances arising after the date hereof, or to reflect the occurrence of or non-occurrence of any future events. Past performance is not a reliable indicator of future performance. Actinogen Medical does not make any guarantee, representation or warranty as to the likelihood of achievement or reasonableness of any forward-looking statements and there can be no assurance or guarantee that any forward-looking statements will be realized.